Intracranial Stenosis
A comprehensive guide to using TCD for detecting intracranial artery narrowing. Review clinical citations on sensitivity, specificity, and its role in acute stroke care.
What Is Intracranial Stenosis?
Intracranial atherosclerotic disease (ICAD) is characterized by the narrowing or blockage of arteries within the brain due to the accumulation of atheromatous plaques in the arterial walls. 1 It is one of the most common causes of ischemic stroke worldwide, estimated to cause 20–40 per 100,000 cerebral infarctions globally. 1 ICAD is judged to be causal in at least 10% of ischemic stroke cases worldwide, and as much as 50% of ischemic strokes in people of Asian ethnicity. 2 The risk of recurrent stroke can be as high as 25%–30% within 2 years after the initial stroke, and patients with ≥70% stenosis face a 1-year recurrent stroke rate exceeding 20% — one of the highest among common causes of stroke. 1 3
Estimated
ischemic strokes occur in the United States every year.
The risk of recurrent stroke can be as high as
within 2 years after the initial stroke
The Role of Transcranial Doppler (TCD) in Detecting Intracranial Stenosis
Transcranial Doppler (TCD) is a non-invasive, portable, and radiation-free diagnostic technique that uses low-frequency ultrasonic waves (≤2 MHz) to evaluate blood flow velocity and cerebrovascular hemodynamics in real time. 4 5 TCD allows continuous bedside monitoring and provides real-time physiologic information on cerebral blood flow that can be combined with structural imaging data. 4
TCD is considered one of the most practical techniques for tracking vascular alterations in response to treatment and is increasingly used in the evaluation of cerebrovascular disease because it allows continuous measurements, real-time responses, and bedside operation. 5
Diagnostic Accuracy of TCD for Intracranial Stenosis
A Cochrane systematic review of nine studies (493 participants) found that TCD and transcranial colour Doppler (TCCD) demonstrated a summary sensitivity of 95% and specificity of 95% for detecting stenosis or occlusion of intracranial arteries in people with acute ischaemic stroke. 6 The review concluded that TCD, administered by professionals with adequate experience, can provide useful diagnostic information for detecting stenosis or occlusion of intracranial vessels, especially where CT or MR-based vascular imaging are not immediately available. 6
A landmark study by Felberg et al. found that TCD had a sensitivity of 93.9% and specificity of 91.2% for identifying ≥50% intracranial arterial stenosis across all vessels. For the middle cerebral artery (MCA) specifically, a mean flow velocity (MFV) threshold of ≥100 cm/s provided the optimal sensitivity and specificity trade-off for detecting ≥50% stenosis. 7
A comparative analysis of TCD and MRA confirmed that TCD has higher specificity and accuracy than cranial MRA for screening intracranial stenosis, supporting TCD as a convenient, safe, and reproducible imaging modality, especially for evaluating the MCA. 5 8
How TCD Detects Intracranial Stenosis
TCD identifies intracranial stenosis through characteristic hemodynamic changes 9:
Elevated mean flow velocities (MFV) at the site of stenosis — the hallmark finding
Turbulence and spectral broadening in the Doppler waveform
Decreased pulsatility index (PI) distal to the stenosis, indicating reduced downstream vascular resistance as the brain compensates for diminished perfusion
Post-stenotic waveform patterns (delayed systolic acceleration) in segments distal to the narrowing
Post-stenotic waveform patterns (delayed systolic acceleration) in segments distal to the narrowing
Patients with stroke and severe (>70%) intracranial atherosclerotic disease are at the highest risk of stroke recurrence. TCD shows high diagnostic accuracy against CT angiography (CTA) in evaluating intracranial arterial stenosis/occlusion in patients with acute ischemic stroke. 9
Key Arteries Assessed by TCD
| Artery | Window | Depth (mm) | Flow Direction | Normal MFV (cm/s) |
|---|---|---|---|---|
|
Middle Cerebral (MCA)
|
Temporal
|
30–60
|
Toward probe
|
55 ± 12
|
|
Anterior Cerebral (ACA)
|
Temporal
|
60-75
|
Away
|
50 ± 11
|
|
Posterior Cerebral (PCA)
|
Temporal
|
60–70
|
Bidirectional
|
40 ± 10
|
|
Basilar (BA)
|
Occipital
|
80–110
|
Away
|
41 ± 10
|
|
Vertebral (VA)
|
Occipital
|
60–80
|
Away
|
38 ± 10
|
|
Internal Carotid (ICA)
|
Orbital
|
60–80
|
Bidirectional
|
45 ± 15
|
Source: American Academy of Neurology TCD guidelines 4
Why TCD for Intracranial Stenosis Screening?
- Non-invasive & radiation-free — no contrast agents or ionizing radiation required 4 5
- Real-time bedside monitoring — ideal for acute stroke settings and ICU environments 5 6
- Cost-effective — significantly less expensive than CTA, MRA, or digital subtraction angiography 4
- Repeatable — enables serial monitoring of stenosis progression or response to treatment 5
- High diagnostic accuracy — 95% sensitivity and 95% specificity for intracranial stenosis/occlusion 6
- Collateral circulation assessment — TCD can evaluate compensatory blood flow pathways when primary arteries are stenosed or occluded 5
Clinical Significance
Early detection of intracranial stenosis is critical. The WASID trial found a 23% annual risk of stroke in patients with ischemic stroke due to ≥70% stenosis, while the SAMMPRIS trial demonstrated that maximal medical therapy reduced this to 12.6% per year. 3 TCD enables timely identification of at-risk patients, supporting physicians in clinical decision-making for stroke prevention and management.
Book a Live Demo
Let's Get started
Discover the future of automated Transcranial Doppler technology. Schedule a brief demo with our specialists to see how non-invasive, robotic TCD fits into your hospital’s workflow.
With real-time information, clinical teams can make more informed decisions about patient management, leading to reduced length of stay and improving patient outcomes.
With the NeuraSignal Platform, healthcare professionals can detect and manage complications more quickly, helping to prevent adverse outcomes, reduce hospital readmissions, and ultimately leading to better patient satisfaction.
References
- Epidemiology, Pathophysiology, and Imaging of Atherosclerotic Intracranial Disease. Stroke, AHA Journals.
- Bala F, et al. Prevalence of Intracranial Atherosclerotic Disease in Patients with Low-Risk Transient or Persistent Neurologic Events. AJNR, 2022;43(3):376-380.
- Intracranial Atherosclerotic Disease. Neurology, 2022.
- Pan Y, et al. Transcranial Doppler Ultrasonography as a Diagnostic Tool for Cerebrovascular Disorders. Front. Hum. Neurosci., 2022;16:841809.
- Wan Y, et al. Application of transcranial Doppler in cerebrovascular diseases. Front. Aging Neurosci., 2022;14:1035086.
- Mattioni A, et al. Transcranial Doppler sonography for detecting stenosis or occlusion of intracranial arteries in people with acute ischaemic stroke. Cochrane Database Syst Rev, 2020;2(2):CD010722.
- Felberg RA, et al. Screening for intracranial stenosis with transcranial Doppler: the accuracy of mean flow velocity thresholds. J Neuroimaging, 2002;12(1):9-14.
- Mowla A, et al. Transcranial Doppler and magnetic resonance angiography assessment of intracranial stenosis: An analysis of screening modalities. PMC, 2020.
- Kim J. Pictorial Essay: Transcranial Doppler Findings of the Intracranial and Extracranial Diseases. J Neurosonol Neuroimag, 2019;11(1):2-21.
Disclaimer of Information & Content
The information provided on the NeuraSignal website is intended for educational and informational purposes only and should not be construed as medical advice, a diagnostic opinion, or a guarantee of clinical outcome. While NeuraSignal strives to present accurate and up-to-date information sourced from peer-reviewed literature and reputable clinical references, NeuraSignal makes no representations or warranties regarding the completeness, accuracy, reliability, or timeliness of any content presented herein. No individual, including patients currently under clinical evaluation, should rely on the information, tools, or resources available on this website for self-diagnosis, self-treatment, or as a substitute for professional medical consultation. Clinical decisions should always be made in partnership with a qualified healthcare provider. NeuraSignal expressly disclaims any liability arising from the use or interpretation of the content on this website.